Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 5
2019 9
2020 16
2021 23
2022 29
2023 24
2024 21
2025 25
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
Overall survival at 24 months was also greater with apalutamide than with placebo (82.4% in the apalutamide group vs. 73.5% in the placebo group; hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005). The frequency of grade 3 or 4 adverse events was 42.2% i …
Overall survival at 24 months was also greater with apalutamide than with placebo (82.4% in the apalutamide group vs. 73.5% in …
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N. Chi KN, et al. J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29. J Clin Oncol. 2021. PMID: 33914595 Clinical Trial.
Herein, we report final efficacy and safety results after unblinding and placebo-to-apalutamide crossover. METHODS: Patients with mCSPC (N = 1,052) were randomly assigned 1:1 to receive apalutamide (240 mg QD) or placebo plus ADT. ...RESULTS: With a median follow-up …
Herein, we report final efficacy and safety results after unblinding and placebo-to-apalutamide crossover. METHODS: Patients with mCS …
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. ...Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to …
BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. …
Apalutamide and Overall Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ. Smith MR, et al. Eur Urol. 2021 Jan;79(1):150-158. doi: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6. Eur Urol. 2021. PMID: 32907777 Free article. Clinical Trial.
Subsequent life-prolonging therapy was received by 371 (46%) patients in the apalutamide arm and by 338 (84%) patients in the placebo arm including 59 patients who received apalutamide after crossover. ...There was a 22% reduction in the hazard of death in the ap …
Subsequent life-prolonging therapy was received by 371 (46%) patients in the apalutamide arm and by 338 (84%) patients in the placebo …
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Merseburger AS, Agarwal N, Bhaumik A, Lefresne F, Karsh LI, Pereira de Santana Gomes AJ, Soto ÁJ, Given RW, Brookman-May SD, Mundle SD, McCarthy SA, Uemura H, Chowdhury S, Chi KN, Bjartell A. Merseburger AS, et al. Eur J Cancer. 2023 Nov;193:113290. doi: 10.1016/j.ejca.2023.113290. Epub 2023 Aug 11. Eur J Cancer. 2023. PMID: 37708629 Free article. Clinical Trial.
Apalutamide improved other clinical outcomes regardless of subgroup, with similar safety profiles. ...CONCLUSION: TITAN patients derived a robust benefit with apalutamide plus ADT regardless of disease volume and timing of metastasis presentation without differences …
Apalutamide improved other clinical outcomes regardless of subgroup, with similar safety profiles. ...CONCLUSION: TITAN patients deri …
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN.
Rodriguez-Vida A, Borque A, Lopez-Campos F, Soto AJ, Garcillan B, Vidal C, Lencart J, Bhaumik A, Mundle SD, Sanden SV, Chi KN, Bjartell A, Agarwal N, Merseburger AS. Rodriguez-Vida A, et al. Eur Urol Oncol. 2025 Oct;8(5):1311-1320. doi: 10.1016/j.euo.2025.07.002. Epub 2025 Sep 29. Eur Urol Oncol. 2025. PMID: 41027802 Free article. Clinical Trial.
Addition of apalutamide to ADT was beneficial across other endpoints and in patients with lung but no liver metastases and regardless of pain at baseline. ...CONCLUSIONS AND CLINICAL IMPLICATIONS: These findings provide strong evidence for early intensification with apa …
Addition of apalutamide to ADT was beneficial across other endpoints and in patients with lung but no liver metastases and regardless …
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, Mai C, Laenen A, Raskin Y, Van Haute C, Goeman L, De Meerleer G, Berghen C, Devlies W, Claessens F, Van Poppel H, Everaerts W, Joniau S. Devos G, et al. Eur Urol. 2023 Jun;83(6):508-518. doi: 10.1016/j.eururo.2022.09.009. Epub 2022 Sep 24. Eur Urol. 2023. PMID: 36167599 Clinical Trial.
RESULTS AND LIMITATIONS: Patients were randomized to neoadjuvant degarelix + apalutamide (n = 45) or degarelix + matching placebo (n = 44) for 12 wk and underwent RP. ...PATIENT SUMMARY: In this study, we looked at the difference in pathological responses in high-risk pros …
RESULTS AND LIMITATIONS: Patients were randomized to neoadjuvant degarelix + apalutamide (n = 45) or degarelix + matching placebo (n …
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Chowdhury S, et al. Ann Oncol. 2023 May;34(5):477-485. doi: 10.1016/j.annonc.2023.02.009. Epub 2023 Feb 27. Ann Oncol. 2023. PMID: 36858151 Free article. Clinical Trial.
By 3 months of apalutamide treatment, best deep PSA decline of 90% or to 0.2 ng/ml occurred in 59% and 51% of apalutamide- and in 13% and 18% of placebo-treated patients, respectively. ...Similar results were observed at landmark 6 and 12 months of apalutamide …
By 3 months of apalutamide treatment, best deep PSA decline of 90% or to 0.2 ng/ml occurred in 59% and 51% of apalutamide- a …
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
Merseburger AS, Agarwal N, Bjartell A, Uemura H, Soto AJ, Bhaumik A, Böhm J, Tran N, Krochmann N, Nematian-Samani M, Mundle SD, Brookman-May SD, Lopez-Gitlitz A, McCarthy SA, Chi K, Chowdhury S. Merseburger AS, et al. BJU Int. 2024 Dec;134(6):982-991. doi: 10.1111/bju.16449. Epub 2024 Jun 28. BJU Int. 2024. PMID: 38940282 Clinical Trial.
RESULTS: By 3 months, more patients achieved UL1 and UL2 with apalutamide (38% and 23%) vs placebo (15% and 5%). In the apalutamide-treated patients, UL2 vs PSA >0.2 ng/mL at landmark 3 months was associated with significantly longer rPFS (hazard ratio [HR] 0.28, …
RESULTS: By 3 months, more patients achieved UL1 and UL2 with apalutamide (38% and 23%) vs placebo (15% and 5%). In the apalutamid …
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Roumiguié M, Paoletti X, Neuzillet Y, Mathieu R, Vincendeau S, Kleinclauss F, Mejean A, Guy L, Timsit MO, Lebret T. Roumiguié M, et al. Future Oncol. 2021 May;17(14):1811-1823. doi: 10.2217/fon-2020-1104. Epub 2021 Feb 5. Future Oncol. 2021. PMID: 33543650
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide, enzalutamide and darolutamide in Phase III clinical trials involving patients with nonmetastatic castration-resistant prostate cancer was performed. ...Three pivotal trials were identifie …
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide, enzalutamide and darolutamide in Phase III clin …
132 results